Aller au contenu principal
Accès ouvert déclaré2021article

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19

216Citations signalées
80Institutions associées
16Pays d’affiliation

Résumé fourni par la source

IMPORTANCE: The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive. OBJECTIVE: To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: The ongoing Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) enrolled and randomized 4763 adults with suspected or confirmed COVID-19 between March 9, 2020, and January 18, 2021, within at least 1 domain; 2011 critically ill adults were randomized to open-label interventions in the immunoglobulin domain at 129 sites in 4 countries. Follow-up ended on April 19, 2021. INTERVENTIONS: The immunoglobulin domain randomized participants to receive 2 units of high-titer, ABO-compatible convalescent plasma (total volume of 550 mL ± 150 mL) within 48 hours of randomization (n = 1084) or no convalescent plasma (n = 916). MAIN OUTCOMES AND MEASURES: The primary ordinal end point was organ support-free days (days alive and free of intensive care unit-based organ support) up to day 21 (range, -1 to 21 days; patients who died were assigned -1 day). The primary analysis was an adjusted bayesian cumulative logistic model. Superiority was defined as the posterior probability of an odds ratio (OR) greater than 1 (threshold for trial conclusion of superiority >99%). Futility was defined as the posterior probability of an OR less than 1.2 (threshold for trial conclusion of futility >95%). An OR greater than 1 represented improved survival, more organ support-free days, or both. The prespecified secondary outcomes included in-hospital survival; 28-day survival; 90-day survival; respiratory support-free days; cardiovascular support-free days; progression to invasive mechanical ventilation, extracorporeal mechanical oxygenation, or death; intensive care unit length of stay; hospital length of stay; World Health Organization ordinal scale score at day 14; venous thromboembolic events at 90 days; and serious adverse events. RESULTS: Among the 2011 participants who were randomized (median age, 61 [IQR, 52 to 70] years and 645/1998 [32.3%] women), 1990 (99%) completed the trial. The convalescent plasma intervention was stopped after the prespecified criterion for futility was met. The median number of organ support-free days was 0 (IQR, -1 to 16) in the convalescent plasma group and 3 (IQR, -1 to 16) in the no convalescent plasma group. The in-hospital mortality rate was 37.3% (401/1075) for the convalescent plasma group and 38.4% (347/904) for the no convalescent plasma group and the median number of days alive and free of organ support was 14 (IQR, 3 to 18) and 14 (IQR, 7 to 18), respectively. The median-adjusted OR was 0.97 (95% credible interval, 0.83 to 1.15) and the posterior probability of futility (OR <1.2) was 99.4% for the convalescent plasma group compared with the no convalescent plasma group. The treatment effects were consistent across the primary outcome and the 11 secondary outcomes. Serious adverse events were reported in 3.0% (32/1075) of participants in the convalescent plasma group and in 1.3% (12/905) of participants in the no convalescent plasma group. CONCLUSIONS AND RELEVANCE: Among critically ill adults with confirmed COVID-19, treatment with 2 units of high-titer, ABO-compatible convalescent plasma had a low likelihood of providing improvement in the number of organ support-free days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707.

Institutions

Berry & Associates (United States)NHS Blood and TransplantSt. Michael's HospitalUniversity of TorontoUniversity of British ColumbiaIntensive Care National Audit & Research CentreKing's College - North CarolinaKing's College LondonGuy's and St Thomas' NHS Foundation TrustUniversity of ManitobaUniversity of OxfordOxford BioMedica (United Kingdom)Université LavalMonash HealthMonash UniversityUniversity of PittsburghImperial College Healthcare NHS TrustImperial College LondonUniversité Paris-SaclayHôpital Raymond-PoincaréKing Saud bin Abdulaziz University for Health SciencesKing Abdullah International Medical Research CenterNational Guard Health AffairsMcMaster UniversityUniversité de MontréalUtrecht UniversityUniversity Medical Center UtrechtWelsh GovernmentUniversity Hospitals Bristol NHS Foundation TrustUniversity of BristolUniversity Hospitals Bristol and Weston NHS Foundation TrustJena University HospitalCenter for Effective Global ActionSunnybrook Health Science CentreQueen's UniversityHealth Sciences CentreKingston Health Sciences CentreCanadian Blood ServicesAlfred HealthNational University of SingaporeAustralian Red Cross LifebloodUniversity of AmsterdamOttawa HospitalOttawa Hospital Research InstituteAntwerp University HospitalWestern Sydney UniversityMahidol Oxford Tropical Medicine Research UnitMedical Research Institute of New ZealandChildren's Hospital of PittsburghThe University of TokyoUniversité de SherbrookeUniversity Health NetworkThe University of Western AustraliaQueen's University BelfastAuckland City HospitalUPMC Health SystemUniversity College DublinSt. Vincent's University HospitalUniversity of AucklandScottish National Blood Transfusion ServiceThe University of MelbournePeter Doherty InstituteUniversidad de La SabanaHéma-QuébecCentre Hospitalier Universitaire Sainte-JustineSt. Marianna University School of MedicineYokohama City Seibu HospitalHospital Israelita Albert EinsteinRadboud University NijmegenRadboud University Medical CenterRadboud Institute for Molecular Life SciencesUniversity of EdinburghUniversity of California, Los AngelesUCLA Medical CenterHarbor–UCLA Medical CenterAddenbrooke's HospitalSt John of God Subiaco HospitalSt John of God HospitalSt Thomas' HospitalSt. Thomas Hospital

Sujets associés

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchSepsis Diagnosis and Treatment

BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.